Anzeige
Mehr »
Login
Samstag, 11.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Innocan Pharma News: Unfassbare Studie - LPT-Therapie bewahrt Patient vor dem Tod!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QLX7 | ISIN: US4884452065 | Ticker-Symbol: 1GDA
Tradegate
10.05.24
17:55 Uhr
4,540 Euro
+0,060
+1,34 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ZEVRA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ZEVRA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
4,3804,54010.05.
4,4004,58010.05.

Aktuelle News zur ZEVRA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoZEVRA THERAPEUTICS, INC. - 10-Q, Quarterly Report1
DoEarnings call: Zevra Therapeutics reports progress in Q1 20241
DoZevra Therapeutics, Inc. (ZVRA) Q1 2024 Earnings Call Transcript4
MiZEVRA THERAPEUTICS, INC. - 8-K, Current Report-
MiZevra Therapeutics GAAP EPS of -$0.40 beats by $0.08, revenue of $3.42M misses by $0.34M1
DiZevra Therapeutics Q1 2024 Earnings Preview2
01.05.Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 20241
29.04.Zevra Therapeutics' President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024112CELEBRATION, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane...
► Artikel lesen
15.04.Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting53The oral presentation highlighted data from Zevra's Expanded Access Program demonstrating a consistent safety profile CELEBRATION, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc....
► Artikel lesen
10.04.Zevra Therapeutics retires existing debt with new $100M credit facility2
10.04.ZEVRA THERAPEUTICS, INC. - 8-K, Current Report2
10.04.Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility98CELEBRATION, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that it has entered into...
► Artikel lesen
01.04.ZEVRA THERAPEUTICS, INC. - 10-K, Annual Report1
01.04.Zevra Therapeutics, Inc. (ZVRA) Q4 2023 Earnings Call Transcript2
01.04.Earnings call: Zevra Therapeutics reports progress and financials for Q4 20233
29.03.Zevra Therapeutics Inc reports results for the quarter ended in December - Earnings Summary2
28.03.Zevra Therapeutics: Q4 Earnings Insights2
28.03.Zevra Therapeutics GAAP EPS of -$1.30 misses by $0.12, revenue of $27.46M beats by $1.48M3
28.03.Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates462Launch of OLPRUVA® underway Topline results from KP1077 phase 2 study demonstrate clinically meaningful benefits for key IH symptoms Q4 2023 net revenue of $13.2M, and FY 2023 net revenue of $27.5M...
► Artikel lesen
28.03.ZEVRA THERAPEUTICS, INC. - 8-K, Current Report2
Seite:  Weiter >>
60 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1